Neurology Biochemistry and molecular biology Screening and monitoring Research and Innovations

Amyloid Seeds Emerge as Blood Biomarker

Plasma aggregation activity separates Alzheimer’s disease from non-Alzheimer’s dementias

09/08/2026 News 3 min read

Share

Clinical Scorecard: Amyloid Seeds Emerge as Blood Biomarker

At a Glance

Category	Detail
Condition	Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease
Key Mechanisms	Detection of amyloid beta aggregation seeding activity in plasma using protein misfolding cyclic amplification
Target Population	Patients with Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease, and other dementias
Care Setting	Clinical assessment in a hospital setting

Key Highlights

Blood test distinguishes Alzheimer's disease and MCI from normal cognition and other dementias
Assay has an area under the curve of 0.93 for Alzheimer's disease vs. normal cognition
Results available within 24 hours
Higher plasma seeding activity correlates with poorer cognitive performance
Validation needed in diverse populations

Guideline-Based Recommendations

Diagnosis

Use clinical criteria for diagnosing Alzheimer's disease and MCI

Management

Consider blood test for distinguishing Alzheimer's disease from other dementias

Monitoring & Follow-up

Monitor cognitive performance and dementia severity in relation to plasma seeding activity

Risks

Limitations include reliance on clinical criteria and lack of neuropathologic confirmation

Patient & Prescribing Data

549 patients including cognitively unimpaired, MCI, and dementia patients

Test performance similar in discovery and validation groups

Clinical Best Practices

Assess amyloid beta seeding activity in patients with suspected Alzheimer's disease
Utilize the assay in conjunction with clinical evaluations

Related Resources & Content

Chinese Medical Journal